CHMP Backs Aflibercept (Eylea) for Visual Impairment Caused by CRVO

The therapeutic indications for aflibercept (Eylea, Bayer Pharma AG) should include treatment of visual impairment caused by macular edema secondary to central retinal vein occlusion in adults.
International Approvals

Full Story →